Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto

A pharmaceutical composition comprising an effective amount of a compound characterized by the structure of Formula I:

• wherein G1 is substituted or unsubstituted pyrrolidine, substituted or unsubstituted piperidine, substituted or unsubstituted piperazine, substituted or unsubstituted imidazolidine, or substituted or unsubstituted pyrazolidine;
• and
• G3 is characterized by the following structure:
• or G3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl;
• wherein G2 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycle;
• or
• a compound characterized by the structure of Formula II:
• wherein G1 is substituted or unsubstituted pyrrolidine, substituted or unsubstituted pyridine, substituted or unsubstituted aryl, substituted or unsubstituted piperidine, substituted or unsubstituted piperazine, substituted or unsubstituted imidazolidine, or substituted or unsubstituted pyrazolidine;
• and
• G3 is characterized by the following structure:
• or G3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl;
• wherein G2 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycle;
• or
• a compound characterized by the structure of Formula III:
• wherein G1 is substituted or unsubstituted pyrrolidine, substituted or unsubstituted pyridine, substituted or unsubstituted aryl, substituted or unsubstituted piperidine, substituted or unsubstituted piperazine, substituted or unsubstituted imidazolidine, or substituted or unsubstituted pyrazolidine;
• and
• G3 is characterized by the following structure:
• or G3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl;
• wherein G2 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycle;
• or
• a compound selected from the group consisting of:
• 3,4-bis((2-(pyrrolidine-1-yl)ethyl)amino)-1,2,5-thiadiazole 1,1-dioxide;
• cyclopropyl (2-(5-isopropylisoxazol-3-yl)pyrrolidin-1-yl)methanone;
• 6-bromo-2-(3,5-dimethoxyphenyl)-4benzo[d][1,3]oxazin-4-one 6-methyl-5-((2-methylpiperidin-1-yl)sulfonyl)pyrimidine-2,4(1H,3H)-dione;
• N-methyl-4,5,6,7,8,9-hexahydro-1H-cycloocta[c]pyrazole-3-carboxamide;
• 2-(5-(pyridin-4-yl)-2H-tetrazol-2-yl)acetic acid;
• 2-(furan-2-yl)-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazin-4-one;
• 3-((5-acetamido-TH-1,2,4-triazol-3-yl)thio)propanoic acid;
• N,N′-(oxybis(4,1-phenylene))bis(2-methylpropanamide);
• 7-(4-ethylpiperazin-1-yl)-5,6-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine;
• 7-fluoro-10-(2-(4-isopropylpiperazin-1-yl)-2-oxoethyl)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a] [1,4]diazepine-5,11(10H,11aH)-dione;
• 2-(tert-butyl)-3-(1-methyl-1H-benzo[d]imidazol-2-yl)-4-oxo-4H-chromen-7-yl pivalate;
• 3-methyl-8-(piperidin-1-yl)-1H-purine-2,6(3H,7H)-dione;
• 2-(3-bromophenyl)-4-oxo-4H-benzo[d][1,3]oxazin-6-yl acetate;
• N-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-3,4,5-trimethoxybenzamide;
• 5-ethyl-N-(pyridin-2-ylmethyl)-5H-[1,2,4]triazino[5,6-b]indol-3-amine;
• 3-((4-chloro-1H-pyrazol-1-yl)methyl)-N-(2-(3-fluorobenzamido)ethyl)-1,2,4-oxadiazole-5-carboxamide;
• 1-(4-(methylthio)benzyl)-4-tosylpiperazine;
• 2-(2-ethylphenylsulfonamido)-5-(4-ethylpiperazin-1-yl)benzoic acid;
• 4((2-methylindolin-1-yl)sulfonyl)benzoic acid;
• 6-bromo-2-(3,5-dimethoxyphenyl)-4H-benzo [d][1,3] oxazin-4-one;
• 2-amino-N-(2,4-difluorophenyl)pyrimidine-5-sulfonamide;
• 3-methyl-8-(piperidin-1-yl)-1H-purine-2,6(3H,7H)-dione;
• 5-chloro-N-(2-oxo-1-phenylpyrrolidin-3-yl)thiophene-2-sulfonamide;
• 3-(pyrrolidin-1-ylsulfonyl)benzoic acid;
• (3,5-dimethyl-1H-pyrazol-1-yl)(3,4,5-trimethoxyphenyl)methanone;
• N-(3,4-difluorophenyl)-2-(8-fluoro-5,11-dioxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a] [1 ,4]diazepin-10(5H)-yl)acetanide;
• 5-(cyclohexylmethyl)-3-(pyridin-2-yl)-1,2,4-oxadiazole;
• ethyl 5-methyl-4-(2-((4-methylbenzyl)amino)-2-oxoethyl)-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate;
• [1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid;
• 1-(2-(piperidin-1-yl)-4,5-dihydro-1H-imidazol-1-yl)butan-1-one;
• (4-(6-chloro-[1,2,4] triazolo [4,3-a]pyridin-3 yl)piperazin-1-yl)(1-phenylcyclopropyl)methanone;
• N-(2,4-difluorophenyl)-2-(5,11-dioxo-2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo [1,2-a][1,4]diazepin-10(5H)-yl)acetamide;
• and
• Ethyl-2,3-dihydro-3-oxo-1,2-benzisothiazole-2-acetate-1,1-dioxide;
• or a pharmaceutical salt thereof, or any combination thereof, and optionally further comprising a pharmaceutically acceptable carrier or excipient.